10-Year watch: does vyndamax keep heart amyloidosis in check?
NCT ID NCT04801329
First seen Apr 09, 2026 · Last updated May 10, 2026 · Updated 2 times
Summary
This study follows 110 adults in Korea with a heart condition called ATTR-CM, where abnormal proteins build up in the heart. Participants take Vyndamax capsules as part of their normal care, and researchers track side effects and heart function over 10 years. The goal is to confirm the drug's safety and how well it controls the disease in everyday use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATTR-CM (TRANSTHYRETIN AMYLOID CARDIOMYOPATHY) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer
Seoul, South Korea
Conditions
Explore the condition pages connected to this study.